XmAb 7195

Drug Profile

XmAb 7195

Alternative Names: XmAb® 7195

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xencor
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Fc gamma receptor IIB antagonists; IgE receptor antagonists; Immunoglobulin E inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Allergic asthma; Hypersensitivity

Highest Development Phases

  • Phase I Allergic asthma; Hypersensitivity

Most Recent Events

  • 28 Feb 2018 Xencor has patent protection for XmAb 7195 in USA and other countries worldwide
  • 07 Nov 2017 XmAb 7195 is available for licensing as of 07 Nov 2017. www.xencor.com
  • 07 Nov 2017 Safety, pharmacokinetics and pharmacodynamics data from a phase I trial in Allergic asthma and Hypersensitivity released by Xencor
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top